Alzheimer's Drug Discovery Foundation
The Alzheimer’s Drug Discovery Foundation (ADDF) is the only public charity solely dedicated to finding effective drugs for Alzheimer’s disease. Our pioneering biomedical venture philanthropy approach allows us to invest in the most promising drug discovery and development programs around the world in both academic institutions and biopharmaceutical companies. Since our founding in 1998, the ADDF has invested nearly $100 million to support over 500 programs across 18 countries.
Top Sectors
Past deals in Geneve
GliaPharm
Grant in 2023
GliaPharm is a Swiss biotechnology company focused on developing treatments for neurological and psychiatric disorders by targeting glial cells to support brain metabolism. It has developed the GliaX platform to identify drugs that modulate glial activity and energy metabolism. The platform combines high-throughput screening using enzymatic and primary-cell assays with metabolic characterization of compounds in vitro in primary brain cell cultures and in vivo in rodent brains. Research includes various rodent models of brain aging, Alzheimer's disease, and ALS, with selective contract research organizations handling parts of the drug-development process. Founded in 2016 and based in Geneva, GliaPharm pursues glia-mediated neuroprotection and maintenance of cognitive function.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.